Autolus Therapeutics (AUTL) announces the U.S. FDA has granted marketing approval for Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- FDA approves obecabtagene autoleucel for certain type of ALL
- Autolus Therapeutics to present clinical data updates at ASH 2024
- Autolus Therapeutics presents clinical data on obe-cel treatment
- Autolus Therapeutics Highlights Advances at Life Sciences Conference
- Autolus Therapeutics appoints WIll as Chief Development Officer